Thompson Siegel & Walmsley LLC Sells 37,447 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Thompson Siegel & Walmsley LLC trimmed its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 9.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 347,809 shares of the medical equipment provider’s stock after selling 37,447 shares during the period. Thompson Siegel & Walmsley LLC’s holdings in Zimmer Biomet were worth $36,739,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of ZBH. Stonebridge Financial Group LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter worth approximately $25,000. Dunhill Financial LLC raised its stake in Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 218 shares in the last quarter. Ashton Thomas Securities LLC acquired a new stake in shares of Zimmer Biomet during the 3rd quarter worth about $28,000. Brooklyn Investment Group acquired a new position in Zimmer Biomet in the third quarter valued at about $35,000. Finally, Kentucky Trust Co acquired a new stake in Zimmer Biomet during the 4th quarter valued at $39,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Buying and Selling

In other news, SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.95% of the stock is currently owned by insiders.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $104.10 on Thursday. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $133.90. The stock’s 50 day moving average price is $105.65 and its two-hundred day moving average price is $107.05. The firm has a market capitalization of $20.72 billion, a price-to-earnings ratio of 23.39, a P/E/G ratio of 1.95 and a beta of 1.04.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the business posted $2.20 earnings per share. On average, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 21.57%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on ZBH shares. Royal Bank of Canada reduced their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Truist Financial reissued a “hold” rating and issued a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Finally, Stifel Nicolaus lifted their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.